Denise Rageot

Institution: Department of Biomedicine, University of Basel

Address:

Mattenstrasse 28, CH-4058 Basel

Email: denise.rageot@unibas.ch

Phone: +41 61 207 51 40

Research interests:

oncology, small molecule cancer drugs, kinase inhibitors, PI3K/mTOR

Selected publications:

Beaufils, F.; Cmiljanovic N.; Cmiljanovic, V.; Bohnacker, T.; Melone, A.; Marone, R.; Jackson, E.; Zhang, X.; Sele, A.; Borsari, C.; Mestan, J.; Hebeisen, P.; Hillmann, P.; Giese, B.; Zvelebil, M.; Fabbro, D.; Williams, R. L.; Rageot, D.; Wymann, M. "5-(4,6-Dimorpholino-1,3,5-triazin)-4-(trifluoromethyl)pyridine-2-amine (PQR309): a potent, brain-penetrant, orally bioavailable, pan-Class I PI3K/mTOR inhibitor as clinical candidate in oncology." J. Med. Chem. 2017, 60, 7524. doi: 10.1021/acs.jmedchem.7b00930 Bohnacker, T.; Prota, A.; Beaufils, F.; Burke, J.; Melone, A.; Inglis, A.; Rageot, D.; Sele, A.; Cmiljanovic, V.; Cmiljanovic, N.; Bargsten, K.; Aher, A.; Akhmanova, A.; Diaz, J. F.; Fabbro, D.; Zvelebil, M.; Williams, R.; Steinmetz, M.; Wymann, M. "Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention." Nat. Commun. 2017, 8, 14683. doi: 10.1038/ncomms14683.

Members List